オリゴ糖のラットのガラクトサミン肝障害発症に及ぼす影響  [in Japanese] Effects of Oligosaccharides on Galactosamine Hepatitis in Rats  [in Japanese]

Access this Article

Author(s)

    • CHENG Chewchuang
    • 千葉大学園芸学部生物生産科学科 Division of Bioproduction Science, Faculty of Horticulture, Chiba University
    • 太田 剛雄 OHTA Takeo
    • 千葉大学園芸学部生物生産科学科 Division of Bioproduction Science, Faculty of Horticulture, Chiba University
    • 真田 宏夫 SANADA Hiroo
    • 千葉大学園芸学部生物生産科学科 Division of Bioproduction Science, Faculty of Horticulture, Chiba University

Abstract

4週齢のウィスター系雄性ラットを用いて飼料中のオリゴ糖のガラクトサミン肝障害発症に及ぼす影響について検討した。<BRガラクトースを含んでいるラクチュロース, ラフィノース, 2種のガラクトオリゴ糖 (以上ビフィズス菌増殖因子), ガラクトースおよびラクトースにガラクトサミン肝障害発症抑制効果が認められた。<BR>同じビフィズス菌増殖因子であるフラクトオリゴ糖とグルコマンノオリゴ糖にはこのような効果が見られなかった。ビフィズス菌増殖因子が必ずしもガラクトサミン肝障害発症抑制効果を示さない場合があった。<BR>ガラクトサミン肝障害発症抑制にはオリゴ糖中あるいは単糖としてのガラクトースが深く関与していることが明らかにされた。

A study was conducted to examine the effects of dietary undigestible oligosaccharides on the development of galactosamine hepatitis in rats. Four-week-old Wistar rats (weight: 55-70g) were fed diets containing 10% oligosaccharides or monosaccharide besides the standard diet for two weeks after one week of prefeeding with the standard diet. On the last day of feeding, the rats were intraperitoneally injected with D-galactosamine solution (800mg/kg body weight), and 20h later the activities of some plasma enzymes were determined to evaluate the effects of oligosaccharides on the development of galactosamine hepatitis. In the first experiment, lactulose, fructooligosaccharide, gentiooligosaccharide, maltooligosaccharide, glucomannooligosaccharide and galactooligosaccharide (T) ((Gal) <SUB>n</SUB>-β- (1→6) -Gal-β- (1→4) -Glc) were used. As a result, all of the activities of plasma glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase and lactate dehydrogenase in the lackulose group tended to be lower than in the cont ol group, and those in the galactooligosaccharide (T) group were significantly lower than in the other groups. Thus it is considered that the development of galactosamine hepatitis is depressed by dietary galactooligosaccharide (T). However, maltooligosaccharide and glucomannooligosaccharide were shown to have no effect. The results of the second experiment indicated that the development of galactosamine hepatitis is depressed not only by lactulose, raffinose and galactooligosaccharide (B) ((Gal) <SUB>n</SUB>-β- (1→4) -Gal-β- (1→4) -Glc) but also by digestible saccharides such as lactose and galactose in the diet.

Journal

  • Nippon Eiyo Shokuryo Gakkaishi

    Nippon Eiyo Shokuryo Gakkaishi 48(3), 181-187, 1995-06-10

    Japan Society of Nutrition and Food Science

References:  26

  • <no title>

    FERNANDES J.

    Clin. Invest. Med. 17, 218, 1994

    Cited by (1)

  • <no title>

    不破英次

    転移糖と栄養 77, 1984

    Cited by (1)

  • <no title>

    KEPPLER D.

    Exp. Mol. Pat. 9, 279, 1968

    Cited by (1)

  • <no title>

    LIEHR H.

    Hepato-Gastroenterol. 27, 356, 1980

    Cited by (1)

  • <no title>

    MULLER-BERGHAUS G.

    Am. J. Pat. 82, 393, 1976

    Cited by (1)

  • <no title>

    ALEXIEV A.

    Sci. Works Med. Univ. 14, 28, 1992

    Cited by (1)

  • <no title>

    岩城義博

    肝臓 29, 1043, 1988

    Cited by (2)

  • <no title>

    小泉岳夫

    腸内フローラと成人病 157, 1984

    Cited by (1)

  • <no title>

    馬田三夫

    ビフイズス菌の科学 39, 1988

    Cited by (1)

  • <no title>

    ITO M.

    Microb. Ecol. Health Dis. 3, 285, 1990

    Cited by (1)

  • <no title>

    森下芳行

    ビフィズス 6, 11, 1992

    Cited by (2)

  • <no title>

    佐山晃司

    ジャパンフードサイエンス 32, 35, 1993

    Cited by (1)

  • <no title>

    谷本義文

    実験動物の臨床化学 84, 1981

    Cited by (1)

  • <no title>

    American Institute of Nutrition

    J. Nutr. 107, 1340, 1977

    Cited by (8)

  • <no title>

    LIPPI U.

    Clin. Chim. Acta 28, 431, 1970

    Cited by (2)

  • <no title>

    SCHWARTZ M. K.

    Methods Enzymol. 9, 294, 1966

    Cited by (1)

  • <no title>

    GRTIM M.

    Acta Hepato-Gastroenterol. 23, 67, 1976

    Cited by (1)

  • <no title>

    BROITMAN S. A.

    J. Exp. Med. 119, 637, 1964

    Cited by (1)

  • <no title>

    HINO Y.

    J. Clin. Biochem. Nutr. 16, 29, 1994

    Cited by (1)

  • <no title>

    DE GROOT G. H.

    Hepato-Gastroenterol. 30, 240, 1983

    Cited by (1)

  • <no title>

    PAIN J. A.

    Br. J. Surg. 73, 775, 1986

    Cited by (1)

  • <no title>

    谷川久一

    エンドトキシン臨床研究の現状と展望 14, 1989

    Cited by (1)

  • <no title>

    HENDRIKS H. F. J.

    Mech. Ageing Div. 41, 241, 1987

    Cited by (1)

  • <no title>

    LESCH R.

    Exp. Mol. Pat. 12, 59, 1970

    Cited by (1)

  • <no title>

    AROLA H.

    Scand. J. Gastroenterol. 29(suppi. 202), 21, 1994

    Cited by (1)

  • <no title>

    BIRD P. H.

    Br. J. Nutr. 71, 553, 1994

    Cited by (1)

Cited by:  1

Codes

  • NII Article ID (NAID)
    10008562454
  • NII NACSIS-CAT ID (NCID)
    AN00311992
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • ISSN
    02873516
  • NDL Article ID
    3619142
  • NDL Source Classification
    SC226(衛生学・公衆衛生--食品衛生・栄養学)
  • NDL Source Classification
    ZS8(科学技術--医学--解剖学・生理学・生化学)
  • NDL Call No.
    Z19-53
  • Data Source
    CJP  CJPref  NDL  J-STAGE 
Page Top